{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:55:17Z","timestamp":1783551317221,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16734-7","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T04:53:54Z","timestamp":1756702434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data"],"prefix":"10.1038","volume":"15","author":[{"given":"Wei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiezhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"3","key":"16734_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0020-7292(96)02698-7","volume":"54","author":"W Choktanasiri","year":"1996","unstructured":"Choktanasiri, W. et al. Long-Acting Triptorelin for the treatment of endometriosis. Int. J. Gynaecol. Obstet. 54 (3), 237\u2013243 (1996).","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"12","key":"16734_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2165\/11319690-000000000-00000","volume":"29","author":"EA Lundstr\u00f6m","year":"2009","unstructured":"Lundstr\u00f6m, E. A. et al. Triptorelin 6-Month formulation in the management of patients with locally advanced and metastatic prostate cancer. Clin. Drug Investig. 29 (12), 757\u2013765 (2009).","journal-title":"Clin. Drug Investig."},{"issue":"7","key":"16734_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/17512433.2018.1494569","volume":"11","author":"S Bertelloni","year":"2018","unstructured":"Bertelloni, S. et al. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty. Expert Rev. Clin. Pharmacol. 11 (7), 659\u2013667 (2018).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"3","key":"16734_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2165\/11202230-000000000-00000","volume":"70","author":"GM Keating","year":"2010","unstructured":"Keating, G. M. Triptorelin embonate (6-Month Formulation). Drugs 70 (3), 347\u2013353 (2010).","journal-title":"Drugs"},{"issue":"2","key":"16734_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/8756-3282(94)00038-2","volume":"16","author":"JE Compston","year":"1995","unstructured":"Compston, J. E. et al. The effects of Gonadotrophin-Releasing hormone agonists on Iliac crest cancellous bone structure in women with endometriosis. Bone 16 (2), 261\u2013267 (1995).","journal-title":"Bone"},{"issue":"4","key":"16734_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0015-0282(98)00019-3","volume":"69","author":"A Bergqvist","year":"1998","unstructured":"Bergqvist, A. et al. Effects of Triptorelin versus placebo on the symptoms of endometriosis. Fertil. Steril. 69 (4), 702\u2013708 (1998).","journal-title":"Fertil. Steril."},{"issue":"6","key":"16734_CR7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.fertnstert.2003.12.020","volume":"81","author":"AYK Wong","year":"2004","unstructured":"Wong, A. Y. K. & Tang, L. An Open and Randomized Study Comparing the Efficacy of Standard Danazol and Modified Triptorelin Regimens for Postoperative Disease Management of Moderate to Severe Endometriosis.\u00a0. Fertility and sterility, 81(6), 1522\u20131527 (2004).","journal-title":"Fertility and sterility,"},{"issue":"1","key":"16734_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0028-2243(94)02016-8","volume":"59","author":"U Cirkel","year":"1995","unstructured":"Cirkel, U., Ochs, H., Schneider, H. P. & Randomized, A. Comparative Trial of Triptorelin Depot (D-Trp6-Lhrh) and Danazol in the Treatment of Endometriosis.. European journal of obstetrics, gynecology, and reproductive biology 59(1), 61\u201369 (1995).","journal-title":"European journal of obstetrics, gynecology, and reproductive biology"},{"issue":"8","key":"16734_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1517\/14656566.2014.916279","volume":"15","author":"ULR Maggiore","year":"2014","unstructured":"Maggiore, U. L. R. et al. Triptorelin for the treatment of endometriosis. Expert Opin. Pharmacother. 15 (8), 1153\u20131179 (2014).","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"16734_CR10","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","volume":"182","author":"M Zhang","year":"2023","unstructured":"Zhang, M. et al. Drug-Associated kidney injury in children: A disproportionality analysis of the Fda adverse event reporting system. Eur. J. Pediatrics. 182 (10), 4655\u20134661 (2023).","journal-title":"Eur. J. Pediatrics"},{"key":"16734_CR11","unstructured":"European Medicines Agency. a.H.o.M.A., guideline on good pharmacovigilance practices (Gvp): Annex I - Definitions (Rev 5). EMA\/876333\/2011 rev 5, 26 July 2024."},{"key":"16734_CR12","doi-asserted-by":"crossref","unstructured":"Chen, J. et al. Post-Marketing safety associated with sodium zirconium cyclosilicate: A pharmacovigilance study based on the Fda reporting system. Expert Opin. Drug Saf., : 1\u20138. (2025).","DOI":"10.1080\/14740338.2025.2486310"},{"issue":"D1","key":"16734_CR13","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Pubchem 2023 update. Nucleic Acids Res. 51 (D1), D1373\u2013D1380 (2023).","journal-title":"Nucleic Acids Res."},{"key":"16734_CR14","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Safety analysis of Pemigatinib leveraging the Us food and drug administration adverse event reporting system. Front. Pharmacol. 14, 1194545 (2023).","journal-title":"Front. Pharmacol."},{"issue":"12","key":"16734_CR15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","volume":"41","author":"C Tieu","year":"2018","unstructured":"Tieu, C. & Breder, C. D. A critical evaluation of safety signal analysis using algorithmic standardised Meddra queries. Drug Saf. 41 (12), 1375\u20131385 (2018).","journal-title":"Drug Saf."},{"issue":"9","key":"16734_CR16","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","volume":"21","author":"F Mazhar","year":"2021","unstructured":"Mazhar, F. et al. The impact of Anti-Tnfalpha agents on Weight-Related changes: new insights from a Real-World pharmacovigilance study using the Fda adverse event reporting system (Faers) database. Expert Opin. Biol. Ther. 21 (9), 1281\u20131290 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"16734_CR17","doi-asserted-by":"publisher","first-page":"766125","DOI":"10.3389\/fphar.2021.766125","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Safety of Sglt2 inhibitors: A pharmacovigilance study from 2013 to 2021 based on Faers. Front. Pharmacol. 12, 766125 (2021).","journal-title":"Front. Pharmacol."},{"key":"16734_CR18","doi-asserted-by":"publisher","first-page":"692828","DOI":"10.3389\/fphar.2022.692828","volume":"13","author":"B Wu","year":"2022","unstructured":"Wu, B. et al. Acute kidney injury associated with remdesivir: A comprehensive pharmacovigilance analysis of Covid-19 reports in Faers. Front. Pharmacol. 13, 692828 (2022).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"16734_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita, S. et al. Time-to-Onset analysis of Amiodarone-Associated thyroid dysfunction. J. Clin. Pharm. Ther. 45 (1), 65\u201371 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"6","key":"16734_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc, J. L. et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72 (6), 905\u2013908 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10","key":"16734_CR21","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/jcpt.13701","volume":"47","author":"JJ Jiang","year":"2022","unstructured":"Jiang, J. J., Zhao, B. & Li, J. Does Eltrombopag lead to thrombotic events?? A pharmacovigilance study of Thefdaadverse events? reporting system. J. Clin. Pharm. Ther. 47 (10), 1556\u20131562 (2022).","journal-title":"J. Clin. Pharm. Ther."},{"key":"16734_CR22","doi-asserted-by":"crossref","unstructured":"Hu, Y. et al. Colitis following the use of immune checkpoint inhibitors: A Real-World analysis of spontaneous reports submitted to the Fda adverse event reporting system. Int. Immunopharmacol., 84. (2020).","DOI":"10.1016\/j.intimp.2020.106601"},{"issue":"3","key":"16734_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000505376","volume":"43","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. Fractures due to aromatase inhibitor therapy for breast cancer: A Real-World analysis of Faers data in the past 15 years. Oncol. Res. Treat. 43 (3), 96\u2013102 (2020).","journal-title":"Oncol. Res. Treat."},{"key":"16734_CR24","doi-asserted-by":"crossref","unstructured":"Shao, Q. et al. Kidney Injury Following Ibuprofen and Acetaminophen: A Real-World Analysis of Post-Marketing Surveillance Data. Front. Pharmacol. 12 (2021).","DOI":"10.3389\/fphar.2021.750108"},{"key":"16734_CR25","doi-asserted-by":"crossref","unstructured":"Meng, L. et al. Lung cancer adverse events reports for Angiotensin-Converting enzyme inhibitors: data mining of the Fda adverse event reporting system database. Front. Med., 8. (2021).","DOI":"10.3389\/fmed.2021.594043"},{"issue":"7","key":"16734_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T. et al. Data mining of the public version of the Fda adverse event reporting system. Int. J. Med. Sci. 10 (7), 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"16734_CR27","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin, Y. et al. A Real-World pharmacovigilance study of Fda adverse event reporting system (Faers) events for osimertinib. Sci. Rep. 12 (1), 19555 (2022).","journal-title":"Sci. Rep."},{"issue":"1537","key":"16734_CR28","first-page":"7","volume":"60","author":"Triptorelin (Triptodur) for Central Precocious Puberty","year":"2018","unstructured":"Triptorelin (Triptodur) for Central Precocious Puberty. Med. Lett. Drugs Ther., 60(1537): 7\u20138. (2018).","journal-title":"Med. Lett. Drugs Ther."},{"key":"16734_CR29","doi-asserted-by":"crossref","unstructured":"Klein, K. et al. Efficacy and safety of Triptorelin 6-Month formulation in patients with central precocious puberty. J. Pediatr. Endocrinol. Metab., . (2016).","DOI":"10.1515\/jpem-2015-0376"},{"issue":"1","key":"16734_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/fon.12.158","volume":"9","author":"G Ploussard","year":"2013","unstructured":"Ploussard, G. & Mongiat-Artus, P. Triptorelin in the Management of Prostate Cancer. Future oncology 9(1), 93\u2013102 (2013).","journal-title":"Future oncology"},{"issue":"2","key":"16734_CR31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","volume":"37","author":"A Farkouh","year":"2019","unstructured":"Farkouh, A. et al. Sex-Related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: A review of the literature. Adv. Therapy. 37 (2), 644\u2013655 (2019).","journal-title":"Adv. Therapy"},{"issue":"6","key":"16734_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000248311","volume":"84","author":"Y Zopf","year":"2009","unstructured":"Zopf, Y. et al. Gender-Based differences in drug prescription: relation to adverse drug reactions. Pharmacology 84 (6), 333\u2013339 (2009).","journal-title":"Pharmacology"},{"issue":"1","key":"16734_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2003","unstructured":"Mangoni, A. A. & Jackson, S. H. D. Age-Related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br. J. Clin. Pharmacol. 57 (1), 6\u201314 (2003).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"16734_CR34","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/ijerph9072444","volume":"9","author":"S Ezoe","year":"2012","unstructured":"Ezoe, S. Secondary leukemia associated with the Anti-Cancer agent, etoposide, a topoisomerase Ii inhibitor. Int. J. Environ. Res. Public Health. 9 (7), 2444\u20132453 (2012).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"16734_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. A Real-World disproportionality analysis of olaparib: data mining of the public version of Fda adverse event reporting system. Clin. Epidemiol. 14, 789\u2013802 (2022).","journal-title":"Clin. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16734-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16734-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16734-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:26:44Z","timestamp":1757467604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16734-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16734"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16734-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32042"}}